结直肠癌
代谢组学
代谢组
医学
肿瘤科
内科学
置信区间
癌症
生物信息学
代谢物
生物
作者
Ivano Bertini,Stefano Cacciatore,Benny Vittrup Jensen,Jakob Vasehus Schou,Julia Sidenius Johansen,Mogens Kruhøffer,Claudio Luchinat,Dorte Lisbet Nielsen,Paola Turano
出处
期刊:Cancer Research
[American Association for Cancer Research]
日期:2011-11-12
卷期号:72 (1): 356-364
被引量:204
标识
DOI:10.1158/0008-5472.can-11-1543
摘要
Earlier detection of patients with metastatic colorectal cancer (mCRC) might improve their treatment and survival outcomes. In this study, we used proton nuclear magnetic resonance ((1)H-NMR) to profile the serum metabolome in patients with mCRC and determine whether a disease signature may exist that is strong enough to predict overall survival (OS). In 153 patients with mCRC and 139 healthy subjects from three Danish hospitals, we profiled two independent sets of serum samples in a prospective phase II study. In the training set, (1)H-NMR metabolomic profiling could discriminate patients with mCRC from healthy subjects with a cross-validated accuracy of 100%. In the validation set, 96.7% of subjects were correctly classified. Patients from the training set with maximally divergent OS were chosen to construct an OS predictor. After validation, patients predicted to have short OS had significantly reduced survival (HR, 3.4; 95% confidence interval, 2.06-5.50; P = 1.33 × 10(-6)). A number of metabolites concurred with the (1)H-NMR fingerprint of mCRC, offering insights into mCRC metabolic pathways. Our findings establish that (1)H-NMR profiling of patient serum can provide a strong metabolomic signature of mCRC and that analysis of this signature may offer an independent tool to predict OS.
科研通智能强力驱动
Strongly Powered by AbleSci AI